365mc, South Korea's leading medical institution specialising in fat reduction treatments, and Israel-based Raziel Therapeutics, a global clinical-stage biopharmaceutical company, have announced a strategic collaboration to jointly advance the clinical and commercial development of RZL-012 in South Korea. RZL-012 is an innovative injectable treatment for focal fat reduction that is currently progressing toward Phase 3 trials.
Leveraging its domestic leadership, 365mc is rapidly expanding its global presence, with successful market entries in Indonesia, Thailand, and Vietnam, and a recent expansion confirmed in the United States, firmly positioning 365mc as a leading international authority in body contouring.
Raziel Therapeutics is developing RZL-012, a New Chemical Entity (NCE) designed to selectively disrupt adipocyte membranes, leading to a reduction in localised subcutaneous fat. The drug is intended for aesthetic applications, including the treatment of submental fat (double chin) and non-surgical body contouring. Clinical trials have shown that RZL-012 induces adipocyte cell death, resulting in a significant and lasting reduction in fat volume at the injection site.
Through this collaboration, the two companies will jointly design and implement the Phase 3 clinical strategy for RZL-012 in South Korea. Leveraging its extensive clinical experience, regulatory expertise, brand-building capabilities, and market access, 365mc will play a critical role in positioning RZL-012 as a best-in-class solution in the Korean aesthetic medicine market.
In addition, the companies will explore the development of a next-generation body contouring protocol by combining RZL-012 with 365mc's proprietary LAMS (Liposuction Assisted Modeling System) procedure. LAMS is an innovative surgical technique for focal fat reduction developed by 365mc and is expected to serve as a platform for global market expansion through an integrated treatment solution.
